最新产品
结构式 | 货号 | 产品名称 | CAS号 |
---|
BCP49700 | 2,3-Diazabicyclo[3.1.1]heptane-4-carboxylic acid, methyl ester, (4S)- 新 | 3034241-21-6 |
BCP28639 | Mutated EGFR-IN-1 新 | 1421372-66-8 | |
Mutated EGFR-IN-1 is a useful intermediate for the inhibitors design for mutated EGFR, such as L858R EGFR, Exonl9 deletion activating mutant and T790M resistance mutant.
|
BCP49699 | Sevabertinib 新 | 2521285-05-0 | |
Sevabertinib is an epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor with antitumor activity.
|
BCP49698 | CMP-5双盐酸盐 新 | 2309409-79-6 | |
CMP-5 hydrochloride is a potent and selective PRMT5 inhibitor, while displays no activity against PRMT1/4/7 enzymes. It selectively blocks S2Me-H4R3 by inhibiting PRMT5 methyltransferase activity on histone preparations.
|
BCP49697 | CBD3063 新 | 1281060-70-5 | |
CBD3063 is a selective, first-in-class, CRMP2-based peptidomimetic small molecule, which allosterically regulates Cav2.2 to achieve analgesia and pain relief without negative side effect profiles.
|
BCP49696 | 广藿香酮 新 | 23800-56-8 | |
Pogostone is isolated from mint and has antibacterial and anticancer activities. Pogostone inhibited gram-negative bacteria and Gram-positive bacteria, and also showed inhibitory effect on Bacillus sclericae, with MIC value of 0.098 µg/mL. Pogostone can induce apoptosis and autophagy.
|
BCP49694 | (2S)-2-cyclopentyl-2-[(5S)-2-[(2-methylpropan-2-yl)oxycarbonyl]-2,7-diazaspiro[4.4]nonan-7-yl]acetic acid 新 | 2865128-45-4 |
BCP49695 | 他氟前列素 16 E-二烯 新 | T16ED |
BCP49693 | 头孢克肟二聚体D 新 | CDD |
BCP49692 | (S)-3-[(S)-4-Boc-吗啉-2-基]-2-(Cbz-氨基)丙酸甲酯 新 | 2641824-60-2 |
BCP49691 | 5-溴-3-(3-((叔丁基二苯基甲硅烷基)氧基)-2,2-二甲基丙基)-2-碘-1H-吲哚 新 | 2641451-43-4 |
BCP49689 | KRAS G12D inhibitor 18 新 | 2922732-54-3 | |
KRAS G12D inhibitor 18 is a potent KRAS G12D inhibitor.
|
BCP49690 | 三羟甲基氨基甲烷盐酸盐 新 | 1185-53-1 | |
Trometamol hydrochloride is a biologically inert amino alcohol of low toxicity, which buffers carbon dioxide and acids in vitro and in vivo. Trometamol hydrochloride is an effective amine compound for pH control in the physiological range.
|
BCP21987 | 间氨基苯甲醛 新 | 1709-44-0 |
BCP21111 | 普托马尼 新 | 187235-37-6 | |
PA-824 is an experimental anti-tuberculosis drug and one of two nitroimidazoles in phase II clinical trials to treat tuberculosis.
|
BCP43839 | 他氟前列腺素杂质 21 新 | 1563176-58-8 |
BCP09072 | 利非西呱 新 | 170632-47-0 | |
YC-1(Lificiguat) is a soluble guanylyl cyclase(sGC) activator; binds to the heme-containing domain of the β subunit with Kd value of 0.6-1.1 μM in the presence of CO.
|
BCP28865 | CD1530 新 | 107430-66-0 | |
CD-1530 is a retinoic acid receptor γ selective agonist.
|
BCP44295 | Exatecan Intermediate 6 新 | 143655-58-7 | |
Exatecan Intermediate 6 is the intermediate of Exatecan(DX-8951) which is a DNA topoisomerase I inhibitor with an IC50 value of 2.2 μM (0.975 μg/mL) that can be used in cancer research.
|
BCP00675 | SB202190 新 | 152121-30-7 | |
SB 202190 is a highly selective, potent and cell-permeable inhibitor of p38 MAP kinase. SB202190 binds within the ATP pocket of the active kinase (Kd = 38 nM, as measured in recombinant human p38), and selectively inhibits the p38α and β isoforms (IC50 = 50 and 100 nM at SAPK2a/p38 and SAPK2b/p38β2 respectively).
|